Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025)

Barinthus Biotherapeutics has reported Cash from Financing Activities for 6 years, with the latest figure at $2000.0 in Q1 2025.

• For the quarter ending Q1 2025, Cash from Financing Activities fell 99.6% year-over-year to $2000.0; the trailing twelve-month figure through Dec 2025 stood at $2000.0 (down 99.91% YoY), and the FY2025 full-year result was $2000.0, down 99.91% from the prior year.
• Cash from Financing Activities for Q1 2025 stood at $2000.0, down from $837000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $121.8 million in Q1 2021, with the low at -$1.4 million in Q3 2021.
• Historically, Cash from Financing Activities has averaged $15.1 million across 5 years, with a median of $358000.0 in 2024.
• The largest YoY upside for Cash from Financing Activities was 5277.78% in 2022 against a maximum downside of 100.13% in 2022.
• Barinthus Biotherapeutics' Cash from Financing Activities stood at $9000.0 in 2021, then soared by 5277.78% to $484000.0 in 2022, then tumbled by 77.48% to $109000.0 in 2023, then surged by 667.89% to $837000.0 in 2024, then plunged by 99.76% to $2000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $2000.0 (Q1 2025), $837000.0 (Q4 2024), and $465000.0 (Q3 2024), per Business Quant data.